Dosing and Administration

Treatment with Acthar

Acthar is a highly purified sterile preparation of adrenocorticotropic hormone in 16% gelatin to provide a prolonged release after subcutaneous or intramuscular injection.1

Acthar offers flexible dosing for patients and providers1

  • Acthar is available as a subcutaneous or intramuscular self-injection, which gives patients the flexibility to take it at home or wherever is best for them1

*Dosage and frequency should be individualized according to the medical condition, severity of the disease, and initial response of the patient.1

Acthar should not be given intravenously. Prolonged use may lead to adrenal insufficiency or recurrent symptoms, which make it difficult to stop treatment. It may be necessary to taper the dose and gradually discontinue.

SC Injection Training Video

Watch step-by-step instructions on how to inject Acthar subcutaneously.

Step-by-step instructions on how to inject Acthar subcutaneously.1:22

Watch Spanish version.

IM Injection Training Video

Watch step-by-step instructions on how to inject Acthar intramuscularly.

Step-by-step instructions on how to inject Acthar subcutaneously.1:19

Watch Spanish version.

IMPORTANT SAFETY INFORMATION

SEE More

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

INDICATIONS

SEE More

H.P. Acthar® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)